CN103052405B - 寡核苷酸螯合物 - Google Patents

寡核苷酸螯合物 Download PDF

Info

Publication number
CN103052405B
CN103052405B CN201180035946.6A CN201180035946A CN103052405B CN 103052405 B CN103052405 B CN 103052405B CN 201180035946 A CN201180035946 A CN 201180035946A CN 103052405 B CN103052405 B CN 103052405B
Authority
CN
China
Prior art keywords
oligonucleotide
chelate
calcium
pharmaceutical composition
chelates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180035946.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN103052405A (zh
Inventor
安德鲁·瓦利恩特
米歇尔·巴齐内
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Replicor Inc
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45594559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103052405(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc filed Critical Replicor Inc
Priority to CN201410046103.1A priority Critical patent/CN103768086B/zh
Publication of CN103052405A publication Critical patent/CN103052405A/zh
Application granted granted Critical
Publication of CN103052405B publication Critical patent/CN103052405B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Saccharide Compounds (AREA)
CN201180035946.6A 2010-08-20 2011-08-18 寡核苷酸螯合物 Active CN103052405B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410046103.1A CN103768086B (zh) 2010-08-20 2011-08-18 寡核苷酸螯合物的用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37525710P 2010-08-20 2010-08-20
US61/375,257 2010-08-20
PCT/CA2011/000956 WO2012021985A1 (en) 2010-08-20 2011-08-18 Oligonucleotide chelate complexes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410046103.1A Division CN103768086B (zh) 2010-08-20 2011-08-18 寡核苷酸螯合物的用途

Publications (2)

Publication Number Publication Date
CN103052405A CN103052405A (zh) 2013-04-17
CN103052405B true CN103052405B (zh) 2015-11-25

Family

ID=45594559

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201180035946.6A Active CN103052405B (zh) 2010-08-20 2011-08-18 寡核苷酸螯合物
CN201410046103.1A Active CN103768086B (zh) 2010-08-20 2011-08-18 寡核苷酸螯合物的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410046103.1A Active CN103768086B (zh) 2010-08-20 2011-08-18 寡核苷酸螯合物的用途

Country Status (35)

Country Link
US (2) US8513211B2 (enExample)
EP (1) EP2605794B1 (enExample)
JP (1) JP5775581B2 (enExample)
KR (3) KR101606495B1 (enExample)
CN (2) CN103052405B (enExample)
AU (1) AU2011291401B2 (enExample)
BR (1) BR112013003875B1 (enExample)
CA (2) CA2855690C (enExample)
CL (1) CL2013000445A1 (enExample)
CO (1) CO6670525A2 (enExample)
CR (1) CR20130069A (enExample)
CU (1) CU20130022A7 (enExample)
CY (1) CY1118207T1 (enExample)
DK (1) DK2605794T3 (enExample)
DO (1) DOP2013000041A (enExample)
EA (1) EA026660B1 (enExample)
EC (1) ECSP13012449A (enExample)
ES (1) ES2598556T3 (enExample)
GT (1) GT201300040A (enExample)
HR (1) HRP20161333T1 (enExample)
HU (1) HUE029521T2 (enExample)
IL (1) IL224237A (enExample)
LT (1) LT2605794T (enExample)
MX (1) MX340294B (enExample)
MY (1) MY160961A (enExample)
NZ (1) NZ606364A (enExample)
PH (1) PH12013500192B1 (enExample)
PL (1) PL2605794T3 (enExample)
PT (1) PT2605794T (enExample)
RS (1) RS55245B1 (enExample)
SG (1) SG187165A1 (enExample)
SI (1) SI2605794T1 (enExample)
SM (1) SMT201600370B (enExample)
WO (1) WO2012021985A1 (enExample)
ZA (1) ZA201300497B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2049664T3 (da) 2006-08-11 2012-01-02 Prosensa Technologies Bv Enkeltstrengede oligonukleotider, som er komplementære til repetitive elementer, til behandling af med DNA-repetitiv-ustabilitet associerede lidelser
JP5646320B2 (ja) 2007-05-11 2014-12-24 アダイニクス， インコーポレイテッド 遺伝子発現と疼痛
EP2614827B1 (en) 2007-10-26 2017-06-28 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
EP4043039A1 (en) 2012-01-27 2022-08-17 BioMarin Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
EP3228712A1 (en) 2012-04-23 2017-10-11 BioMarin Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders
PT2846839T (pt) * 2012-05-10 2019-05-29 Adynxx Inc Formulações para a administração de ingredientes ativos
AR091065A1 (es) * 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
MY168778A (en) * 2012-05-18 2018-12-04 Replicor Inc Oligonucleotide chelate complex-polypeptide compositions and methods
BR112014033004B1 (pt) * 2012-07-03 2021-10-19 Biomarin Technologies B.V. Oligonucleotídeo para tratamento de pacientes com distrofia muscular
IN2015DN01087A (enExample) 2012-08-30 2015-06-26 Replicor Inc
CN113750112A (zh) 2014-07-10 2021-12-07 里普利科股份有限公司 治疗b型肝炎和d型肝炎病毒感染的方法
PT3180434T (pt) 2014-08-15 2019-10-29 Adynxx Inc Chamarizes oligonucleotídicos para o tratamento da dor
WO2016030863A1 (en) 2014-08-29 2016-03-03 Glaxosmithkline Intellectual Property Development Limited Compounds and methods for treating viral infections
MX383293B (es) * 2015-04-23 2025-03-13 Geron Corp Metodos de preparacion de polinucleotidos usando composiciones salinas de cationes multivalentes.
BR112021008539A2 (pt) * 2018-11-08 2021-08-03 Aligos Therapeutics, Inc. polímeros de oligonucleotídeos e métodos de inibição de transporte de antígeno s
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
US20230250125A1 (en) 2020-04-01 2023-08-10 Janssen Biopharma, Inc. Nucleic acid polymers
CA3200094A1 (en) * 2020-11-20 2022-05-27 Aligos Therapeutics, Inc. Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting
WO2022133230A1 (en) 2020-12-18 2022-06-23 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
WO2023281434A1 (en) 2021-07-09 2023-01-12 Janssen Pharmaceuticals, Inc. Use of oligonucleotides for individuals with renal impairment
WO2024255846A1 (en) * 2023-06-16 2024-12-19 Ractigen Therapeutics Oligonucleotide formulation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011143A (en) * 1997-09-12 2000-01-04 Canon Kabushiki Kaisha Artificial nucleic acids and a method of making
US20060293510A1 (en) * 2003-09-08 2006-12-28 Japan Science And Technology Agency Metal complex type nucleic acid
US20070105116A1 (en) * 2003-09-02 2007-05-10 Japan Science And Technology Agency Metal complex type nucleic acid

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2300938A1 (en) * 1997-08-20 1999-02-25 Somagenics, Inc. Antisense and antigene therapeutics with improved binding properties and methods for their use
US6653467B1 (en) * 2000-04-26 2003-11-25 Jcr Pharmaceutical Co., Ltd. Medicament for treatment of Duchenne muscular dystrophy
JP4836366B2 (ja) * 2000-08-25 2011-12-14 雅文 松尾 デュシェンヌ型筋ジストロフィー治療剤
CA2613101A1 (en) * 2005-07-01 2007-01-11 Bioveris Corporation Compositions and methods for detecting, amplifying, and/or isolating nucleic acids
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011143A (en) * 1997-09-12 2000-01-04 Canon Kabushiki Kaisha Artificial nucleic acids and a method of making
US20070105116A1 (en) * 2003-09-02 2007-05-10 Japan Science And Technology Agency Metal complex type nucleic acid
US20060293510A1 (en) * 2003-09-08 2006-12-28 Japan Science And Technology Agency Metal complex type nucleic acid

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Influence of divalent cations on the conformation of phosphorothioate oligodeoxynucleotides:a circular dichroism study;Siddhesh D.Patil等;《nucleic Acids Research》;20000615;第28卷(第12期);2439-2445 *

Also Published As

Publication number Publication date
PH12013500192A1 (enExample) 2013-03-11
US20120046348A1 (en) 2012-02-23
CL2013000445A1 (es) 2013-11-22
SG187165A1 (en) 2013-02-28
EA026660B1 (ru) 2017-05-31
BR112013003875B1 (pt) 2021-10-05
CR20130069A (es) 2013-09-20
CO6670525A2 (es) 2013-05-15
CN103052405A (zh) 2013-04-17
HRP20161333T1 (hr) 2016-12-02
CA2855690A1 (en) 2012-02-23
PL2605794T3 (pl) 2017-01-31
CA2806616A1 (en) 2012-02-23
SMT201600370B (it) 2016-11-10
MX340294B (es) 2016-07-04
US8716259B2 (en) 2014-05-06
KR20150039873A (ko) 2015-04-13
WO2012021985A1 (en) 2012-02-23
EP2605794B1 (en) 2016-07-20
LT2605794T (lt) 2016-10-25
MX2013001668A (es) 2013-07-22
MY160961A (en) 2017-03-31
ECSP13012449A (es) 2013-04-30
KR101606495B1 (ko) 2016-03-28
PT2605794T (pt) 2016-10-25
DOP2013000041A (es) 2017-12-15
HK1184058A1 (zh) 2014-01-17
JP2013536195A (ja) 2013-09-19
CU20130022A7 (es) 2013-04-19
US20130296410A1 (en) 2013-11-07
IL224237A (en) 2015-09-24
DK2605794T3 (en) 2016-10-24
HUE029521T2 (en) 2017-03-28
EA201300259A1 (ru) 2013-12-30
CN103768086A (zh) 2014-05-07
CY1118207T1 (el) 2017-06-28
ES2598556T3 (es) 2017-01-27
HK1198123A1 (en) 2015-03-13
US8513211B2 (en) 2013-08-20
EP2605794A4 (en) 2014-07-02
EP2605794A1 (en) 2013-06-26
KR20150082685A (ko) 2015-07-15
BR112013003875A2 (en) 2018-03-13
GT201300040A (es) 2014-09-02
KR20130099067A (ko) 2013-09-05
JP5775581B2 (ja) 2015-09-09
AU2011291401A1 (en) 2013-01-10
CA2855690C (en) 2015-08-25
PH12013500192B1 (en) 2018-11-23
CN103768086B (zh) 2015-10-14
RS55245B1 (sr) 2017-02-28
SI2605794T1 (sl) 2017-01-31
ZA201300497B (en) 2013-09-25
CA2806616C (en) 2015-08-11
NZ606364A (en) 2014-12-24
AU2011291401B2 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
CN103052405B (zh) 寡核苷酸螯合物
JP6294308B2 (ja) オリゴヌクレオチドキレート錯体方法
CN104349793B (zh) 寡核苷酸螯合物‑多肽组合物和方法
HK1184058B (en) Oligonucleotide chelate complexes
HK1198123B (en) The use of oligonucleotide chelate complexes
HK1206259B (zh) 寡核苷酸螯合物方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1184058

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1184058

Country of ref document: HK